Cargando…
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Ther...
Autores principales: | Jilkova, Zuzana Macek, Kuyucu, Ayca Zeybek, Kurma, Keerthi, Ahmad Pour, Séyédéh Tayébéh, Roth, Gaël S., Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Sturm, Nathalie, Marche, Patrice N., Hainaut, Pierre, Decaens, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834253/ https://www.ncbi.nlm.nih.gov/pubmed/29541403 http://dx.doi.org/10.18632/oncotarget.24298 |
Ejemplares similares
-
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
por: Kurma, Keerthi, et al.
Publicado: (2022) -
Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019) -
Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019) -
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017) -
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017)